Shenglan Tang
Academic Co-Director of Global Health, Duke Kunshan University
Mary D.B.T. and James H. Semans International Distinguished Professor
Research Professor of Global Health
Professor in Population Health Sciences
Appointment:
Topics:
Shenglan Tang
Academic Co-Director of Global Health, Duke Kunshan University
Mary D.B.T. and James H. Semans International Distinguished Professor
Research Professor of Global Health
Professor in Population Health Sciences
Dr. Shenglan Tang is Mary D.B.T. and James Semans Professor at Department of Population Health Science in the Duke University School of Medicine and Research Professor of Global Health in the Duke Global Health Institute (DGHI). He is also a professor of global health at Duke-Kunshan University, and SingHealth-Duke-NUS Global Health Institute in Singapore. Recently Dr. Tang has been re-appointed to be director for global health at Duke Kunshan University, China.
Dr. Tang has more than 30 years of experience undertaking research on health systems reform, disease control and maternal and child health in China and other countries, and has provided consultancy services on health systems strengthening to many international organizations and governments of developing countries. In 2012, Dr. Tang came to Duke from the UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR), based in Geneva, where he was Unit Leader for TB/HIV and Health Systems. Before his assignment at WHO, Tang was a faculty member at Liverpool School of Tropical Medicine in UK and at the School of Public Health of Fudan University (formerly Shanghai Medical University).
Projects
-
Innovation for Vaccine Delivery Research in China
China
-
Feasibility Study of Establishing Day-Care Unit for Hospitals in Sri Lanka
Sri Lanka
-
Supporting Covid-19 Vaccine Delivery in China
China
-
Achieving Health SDGs in China: Developing Evidence-based Policy Options for Action
China
-
Monitoring, Learning and Evaluation for the Implementation of Comprehensive Models of TB Care and Control in China
China
-
Developing and Evaluating Financial Models for TB/MDRTB Care in China
China
Publications
-
Liu X, Yang X, Lyu M, Dai Z, Jing S, Xin Y, et al. Willingness to Undergo Human Papillomavirus Testing Among Men Who Have Sex With Men in China Based on the Information-Motivation-Behavioral Skills Model: Online Cross-Sectional Study. JMIR Public Health Surveill. 2026 Jun 8;12:e85543.Tang S, Du H, Zhao F, Qiao Y. From local pilots to national policy: key issues and challenges in implementing nationwide HPV vaccination in China. Lancet Reg Health West Pac. 2026 May;70:101874.Tang S, Merson M. Transforming WHO: incremental reform is no longer sufficient. Lancet. 2026 Apr 25;407(10539):1580–2.Zhu X, Strachan D, Marthias T, Mahal A, Tang S, McPake B. How do tensions between medical professionalism and financial incentives play out under case-based payment reform in China. Soc Sci Med. 2026 Apr;395:119079.
See more publications at Scholars@Duke

